CorpAcq SPAC Presentation Deck slide image

CorpAcq SPAC Presentation Deck

34 Market Leadership Analysis - Key 3B Comparable Companies Deep Dive Primary End-Markets Diversified Industrials Trade Closest comparable companies have slightly different acquisition strategies based on industry, value-add, and multiples paid, but execution is a key factor Life Sciences Other Key Geographies M&A Approach # of Portfolio Companies # of Acquisitions Per Year Target Business Size Financial Metrics Equity Value ($mm) 3Y EPS CAGR ('19 - '22) LTM Dividend Yield TEV / FY2023E EBITDA TEV / FY2024E EBITDA CorpAcq UK 47 (1) -3 ~$1-30mm EBITDA (2) $1,207 (3) 20.1% Dividend to commence at close 10.3x ΝΑ CorpAcq vs. Key Public Peers Indutrade ADDTECH Nordics, DACH, UK 150 ~10 ~$5-15mm Revenue / ~$1-3mm EBITA $5,049 19.6% 1.3% 18.8x 18.0x Global (>30 Countries) Global (>30 Countries) 235 ~15 ~$5-15mm Revenue / ~$1-3mm EBITA $7,695 21.7% 1.2% 16.4x LIFCO 15.8x 211 ~10 ~$1-40mm Revenue $9,183 22.7% 1.0% 17.9x CHURCHILL CAPITAL VII CorpAcq 18.1x DIPLOMA North America, Europe, Australia 123 ~10 ~$1-35mm Revenue / ~$1-7mm EBIT $5,193 16.0% 2.3% 16.5x 15.1x BEIJER ALMA Europe, Asia, North America 35 ~5 ~$5-65mm Revenue / ~$1-7mm EBIT $1,098 9.9% 2.3% 11.3x 10.2x Source: Company filings and websites; market prices as of 7/28/2023. Note: CorpAcq FY2023E financials are estimates from CorpAcq Management. Assumes USD:GBP exchange ratio of 1.286:1. (1) As of 7/31/2023. (2) Reflects CorpAcq post-money equity value at announcement. (3) Reflects net income CAGR (adjusted for non-controlling interest) rather than EPS.
View entire presentation